SCN SIGNS EXCLUSIVE AGREEMENT FOR COLDIZIN ON THE FRENCH MARKET

Scandinavian Clinical Nutrition (SCN) has entered into an exclusive distribution agreement for Coldizin with Negma Laboratories, one of the top pharmaceutical companies in France.

“I am very glad that SCN has reached an agreement with a partner like Negma Laboratories on the important French market”, says Thomas Christensen, CEO of SCN. “Like SCN, Negma is a company focused on research and products with high standards, and the fact that they are taking on Coldizin is a sign of the potential and quality of the product.”

Negma Laboratories is the fourth largest independent, integrated pharmaceutical group in France, with sales of EUR 120 million in 2006 and 600 employees throughout the country. Coldizin will be sold under private label as a food supplement, and marketed throughout the country through Negma’s strong sales and marketing organization. The launch is planned for the fourth quarter of 2008.

“This is a great opportunity for Coldizin”, says Danilo Copiz, SCN’s VP of Sales who negotiated the contract with Negma. “The product has strong scientific documentation and patent protection, and Negma’s experience of selling high-quality products and their nation-wide distribution makes them an ideal distribution partner.”

Negma was recently acquired by the Indian pharmaceutical and biotechnology major Wockhardt Limited for EUR 195 million, making the company part of a global organization with 6,000 employees of which 1,500 are based in Europe.

For more information, please contact:

Thomas Christensen, CEO, tc@scnutrition.com, +47 922 55 444

Danilo Copiz, VP of Sales, dc@scnutrition.com, +45 2090 8885

Scandinavian Clinical Nutrition AB (publ) works in R&D and sales of scientifically documented products within the field of nutrition (nutraceuticals). Established in 2006, SCN maintains a product portfolio with established trademarks, such as CUUR, Coldizin, Immulina and Ledactin. Core competence and strategic alliances within both R&D and sales, in combination with innovative and scientifically documented products, create the right conditions for profitable growth on the international market. The shares of SCN are traded under the ticker “SCN” on Oslo Axess (www.osloaxess.no) and NGM Equity (www.ngm.se).